Cargando…

Tau as a diagnostic instrument in clinical trials to predict amyloid in Alzheimer's disease

INTRODUCTION: Alzheimer's disease (AD) is characterized by the presence of both amyloid and tau pathology. In vivo diagnosis can be made with amyloid and tau positron emission tomography (PET) imaging. Emergent evidence supports that amyloid and tau accumulation are associated and that amyloid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shcherbinin, Sergey, Morris, Amanda, Higgins, Ixavier A., Tunali, Ilke, Lu, Ming, Deveau, Carmen, Southekal, Sudeepti, Kotari, Vikas, Evans, Cynthia D., Arora, Anupa K., Collins, Emily C., Pontecorvo, Michael, Mintun, Mark A., Sims, John R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432878/ https://www.ncbi.nlm.nih.gov/pubmed/37600216 http://dx.doi.org/10.1002/trc2.12415

Ejemplares similares

Early tau detection in flortaucipir images: validation in autopsy-confirmed data and implications for disease progression
por: Kotari, Vikas, et al.
Publicado: (2023)

Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial
por: Shcherbinin, Sergey, et al.
Publicado: (2022)

A multicentre longitudinal study of flortaucipir ((18)F) in normal ageing, mild cognitive impairment and Alzheimer’s disease dementia
por: Pontecorvo, Michael J, et al.
Publicado: (2019)

Topographic staging of tau positron emission tomography images
por: Schwarz, Adam J., et al.
Publicado: (2018)

Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition
por: Pontecorvo, Michael J., et al.
Publicado: (2017)

Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer’s disease
por: Biel, Davina, et al.
Publicado: (2022)

Magnetic resonance imaging measures of brain volumes across the EXPEDITION trials in mild and moderate Alzheimer's disease dementia
por: Svaldi, Diana Otero, et al.
Publicado: (2022)

Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial
por: Pontecorvo, Michael J., et al.
Publicado: (2022)

PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's disease
por: Pontecorvo, Michael J, et al.
Publicado: (2011)

PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with (18)F-AV-133 (florbenazine) in patients with Alzheimer’s disease and Lewy body disorders
por: Siderowf, Andrew, et al.
Publicado: (2014)

Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease
por: Fagan, Anne M, et al.
Publicado: (2009)

Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease: Results From 2 Phase III Clinical Trials
por: Lu, Ming, et al.
Publicado: (2021)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
por: Mattsson‐Carlgren, Niklas, et al.
Publicado: (2021)

Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer’s disease pathology: a clinicopathological study
por: Pontecorvo, Michael J., et al.
Publicado: (2020)

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease
por: Janelidze, Shorena, et al.
Publicado: (2020)

The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects
por: Smith, Ruben, et al.
Publicado: (2020)

The Amyloid-Tau-Neuroinflammation Axis in the Context of Cerebral Amyloid Angiopathy
por: Cisternas, Pablo, et al.
Publicado: (2019)

Transcriptional Signatures of Tau and Amyloid Neuropathology
por: Castanho, Isabel, et al.
Publicado: (2020)

Membrane-induced tau amyloid fibrils
por: El Mammeri, Nadia, et al.
Publicado: (2023)

Relationship between amyloid and tau levels and its impact on tau spreading
por: Doré, Vincent, et al.
Publicado: (2021)

Cerebrovascular stiffness and flow dynamics in the presence of amyloid and tau biomarkers
por: Rivera‐Rivera, Leonardo A., et al.
Publicado: (2021)

Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition
por: Risacher, Shannon L., et al.
Publicado: (2019)

Amyloid‐dependent and amyloid‐independent effects of Tau in individuals without dementia
por: Therriault, Joseph, et al.
Publicado: (2021)

Increased Medial Temporal Tau Positron Emission Tomography Uptake in the Absence of Amyloid-β Positivity
por: Costoya-Sánchez, Alejandro, et al.
Publicado: (2023)

Amyloid duration is associated with preclinical cognitive decline and tau PET
por: Koscik, Rebecca L., et al.
Publicado: (2020)

Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals
por: Groot, Colin, et al.
Publicado: (2022)

Tau aggregation and its interplay with amyloid-β
por: Nisbet, Rebecca M., et al.
Publicado: (2014)

Small molecules to target tau amyloid aggregation
por: Manglano-Artuñedo, Zoe, et al.
Publicado: (2023)

Beam instrumentation for a tau-charm factory
por: Bosser, Jacques
Publicado: (1994)

Beam instrumentation for a tau-charm factory
por: Bosser, J
Publicado: (1993)

Prediction of Cerebral Amyloid Pathology Based on Plasma Amyloid and Tau Related Markers
por: Chen, Ting-Bin, et al.
Publicado: (2021)

CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease
por: Barthélemy, Nicolas R., et al.
Publicado: (2023)

Detection of Alzheimer's disease amyloid beta 1‐42, p‐tau, and t‐tau assays
por: van Harten, Argonde C., et al.
Publicado: (2021)

Tau post-translational modifications in wildtype and human amyloid precursor protein transgenic mice
por: Morris, Meaghan, et al.
Publicado: (2015)

Convergence of Amyloid-β and Tau Pathologies on Mitochondria In Vivo
por: Eckert, Anne, et al.
Publicado: (2010)

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
por: Gisslén, Magnus, et al.
Publicado: (2009)

Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer's Disease
por: Kametani, Fuyuki, et al.
Publicado: (2018)

The Dichotomy of Alzheimer’s Disease Pathology: Amyloid-β and Tau
por: Ashford, J. Wesson
Publicado: (2019)

Amyloid and Tau Protein Concentrations in Children with Meningitis and Encephalitis
por: Sulik, Artur, et al.
Publicado: (2022)

Amyloid-β-Derived Peptidomimetics Inhibits Tau Aggregation
por: Gorantla, Nalini V., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5fuffc0h739q94p2t3d2mnns9q